176 related articles for article (PubMed ID: 7481562)
1. Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice.
Zhu X; Tommasino M; Vousden K; Sadovnikava E; Rappuoli R; Crawford L; Kast M; Melief CJ; Beverley PC; Stauss HJ
Scand J Immunol; 1995 Nov; 42(5):557-63. PubMed ID: 7481562
[TBL] [Abstract][Full Text] [Related]
2. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein.
Sadovnikova E; Zhu X; Collins SM; Zhou J; Vousden K; Crawford L; Beverley P; Stauss HJ
Int Immunol; 1994 Feb; 6(2):289-96. PubMed ID: 7512375
[TBL] [Abstract][Full Text] [Related]
3. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
Street MD; Doan T; Herd KA; Tindle RW
Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
[TBL] [Abstract][Full Text] [Related]
4. Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells.
Kulkarni AB; Morse HC; Bennink JR; Yewdell JW; Murphy BR
J Virol; 1993 Jul; 67(7):4086-92. PubMed ID: 7685408
[TBL] [Abstract][Full Text] [Related]
5. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects.
Indrová M; Reinis M; Bubeník J; Jandlová T; Bieblová J; Vonka V; Velek J
Folia Biol (Praha); 2004; 50(6):184-93. PubMed ID: 15709713
[TBL] [Abstract][Full Text] [Related]
7. A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour.
Doan T; Herd K; Ramshaw I; Thomson S; Tindle RW
Cancer Immunol Immunother; 2005 Feb; 54(2):157-71. PubMed ID: 15480657
[TBL] [Abstract][Full Text] [Related]
8. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
[TBL] [Abstract][Full Text] [Related]
9. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge.
Lawson CM; Bennink JR; Restifo NP; Yewdell JW; Murphy BR
J Virol; 1994 Jun; 68(6):3505-11. PubMed ID: 7514677
[TBL] [Abstract][Full Text] [Related]
10. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.
Tindle RW; Croft S; Herd K; Malcolm K; Geczy AF; Stewart T; Fernando GJ
Clin Exp Immunol; 1995 Aug; 101(2):265-71. PubMed ID: 7544248
[TBL] [Abstract][Full Text] [Related]
11. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene.
Cheng WF; Hung CF; Chai CY; Hsu KF; He L; Rice CM; Ling M; Wu TC
J Immunol; 2001 May; 166(10):6218-26. PubMed ID: 11342644
[TBL] [Abstract][Full Text] [Related]
13. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
14. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus.
Hiranuma K; Tamaki S; Nishimura Y; Kusuki S; Isogawa M; Kim G; Kaito M; Kuribayashi K; Adachi Y; Yasutomi Y
J Gen Virol; 1999 Jan; 80 ( Pt 1)():187-193. PubMed ID: 9934701
[TBL] [Abstract][Full Text] [Related]
15. Rotavirus-specific cytotoxic T lymphocytes recognize overlapping epitopes in the amino-terminal region of the VP7 glycoprotein.
Buesa J; Raga JV; Colomina J; de Souza CO; Muñoz C; Gil MT
Virology; 1999 May; 257(2):424-37. PubMed ID: 10329553
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.
Herd KA; Harvey T; Khromykh AA; Tindle RW
Virology; 2004 Feb; 319(2):237-48. PubMed ID: 14980484
[TBL] [Abstract][Full Text] [Related]
17. [Experimental study of the immuno-protective activity of recombinant vaccinia virus expressing HPV58 E7].
Luo LQ; Li J; Liu X; Zhang YH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Feb; 25(1):43-6. PubMed ID: 12905606
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
[TBL] [Abstract][Full Text] [Related]
19. Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs).
Tarpey I; Stacey SN; McIndoe A; Davies DH
Vaccine; 1996 Feb; 14(3):230-6. PubMed ID: 8920705
[TBL] [Abstract][Full Text] [Related]
20. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
